Clinical Trial Update: OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating onabotulinumtoxinA for major depressive disorder in adult females has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Allergan | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED | Results posted: 2017-12-19